

UNITED STATES PATENT AND TRADEMARK OFFICE

---

BEFORE THE PATENT TRIAL AND APPEAL BOARD

---

LIQUIDIA TECHNOLOGIES, INC.,  
Petitioner,

v.

UNITED THERAPEUTICS CORPORATION,  
Patent Owner.

---

IPR2020-00770  
Patent 9,604,901 B2

---

Before ERICA A. FRANKLIN, ZHENYU YANG, and  
JOHN E. SCHNEIDER, *Administrative Patent Judges*.

YANG, *Administrative Patent Judge*.

DECISION  
Denying Patent Owner's Request  
on Rehearing of Decision on Institution  
*37 C.F.R. § 42.71(d)*

## INTRODUCTION

Liquidia Technologies, Inc. (“Petitioner”) filed a Petition (Paper 1 (“Pet.”)), seeking an *inter partes* review of claims 1–9 of U.S. Patent No. 9,604,901 B2 (Ex. 1001, “the ’901 patent”). We granted the Petition and instituted *inter partes* review on all challenges to all claims. Paper 7 (“Decision” or “Dec.”). United Therapeutics Corporation (“Patent Owner”) filed a Request for Rehearing of the Decision. Paper 9 (“Req. Reh’g”).

For the reasons expressed below, the Request for Rehearing is denied. As a result, *inter partes* review shall continue on all grounds challenging all claims addressed in the Petition.

## STANDARD OF REVIEW

The party challenging a decision in a request for rehearing bears the burden of showing the decision should be modified. 37 C.F.R. § 42.71(d) (2019). A request for rehearing “must specifically identify all matters the party believes the Board misapprehended or overlooked, and the place where each matter was previously addressed.” *Id.* When rehearing a decision on institution, the Board reviews the decision for an abuse of discretion. 37 C.F.R. § 42.71(c). It is not an abuse of discretion to have made an analysis or conclusion with which a party disagrees. Instead, an abuse of discretion occurs if a decision is based on an erroneous interpretation of law, if a factual finding is not supported by substantial evidence, or if the decision represents an unreasonable judgment in weighing relevant factors. *Arnold P’ship v. Dudas*, 362 F.3d 1338, 1340 (Fed. Cir. 2004).

## ANALYSIS

In our Decision, we determined that Petitioner demonstrated a reasonable likelihood of success in showing that the challenged claims

would have been obvious over the asserted combination of Moriarty and Phares. *See* Dec. 22–28. In its Request for Rehearing, Patent Owner contends that our determination to institute *inter partes* review is improper for three reasons. First, Patent Owner argues that we misapprehended the differences between the prior art and the claims at issue. Reh’g Req. 2–5. Second, Patent Owner argues that we misapprehended the standard for inherency. *Id.* at 5–7. Third, Patent Owner argues that we overlooked objective indicia of nonobviousness. *Id.* at 7–10.

Because we did not expressly address Patent Owner’s arguments with respect to objective indicia of nonobviousness (*see* Paper 6 (“Prelim. Resp.”) 69–71), we address those arguments now. For the reasons explained below, however, we deny the Request for Rehearing because none of Patent Owner’s arguments persuade us of an abuse of discretion in instituting review in this proceeding.

#### *Differences between the Prior Art and Claim 1*

Patent Owner contends that “the Decision mistakenly finds that ‘the combination of Moriarty and Phares teaches the same process steps as challenged claim 1.’” Reh’g Req. 4 (citing Dec. 27). Patent Owner contends that claim 1’s recited steps do not involve isolating the treprostinil intermediate. *Id.* at 2–3. Patent Owner contends that claim 1 differs from Phares and Moriarty because each reference separately describes isolating the treprostinil intermediate. *Id.* at 3. Patent Owner contends that Petitioner relies on the ordinarily skilled artisan being motivated to modify the prior art by removing the isolating step from the Moriarty and Phares processes. *Id.* at 2–3. Because of this modification, Patent Owner contends that “Moriarty

and Phares do not teach the same process steps” resulting in the claimed product. *See id.* at 4. We are not persuaded by Patent Owner’s argument.

As an initial matter, to the extent that Patent Owner attacks the references individually, we emphasize that we consider the combination of the prior art as a whole. *See In re Merck & Co., Inc.*, 800 F.2d 1091, 1097 (Fed. Cir. 1986) (“Non-obviousness cannot be established by attacking references individually where the [challenge] is based upon the teachings of a combination of references.”).

In the Decision, we explained that Phares explicitly describes the Moriarty process in teaching the synthesis of (-)-treprostinil, the enantiomer of (+)-treprostinil. Dec. 25 (citing Ex. 1008, 40). Thus, on the record before us at that time, we “agree[d] with Petitioner that an ordinarily skilled artisan would have combined the process of Moriarty with the step of adding diethanolamine to treprostinil as taught by Phares.” *Id.* The resulting combination of Moriarty and Phares would not involve isolating the treprostinil intermediate and accordingly, teaches the same process steps as challenged claim 1. Having reconsidered the pre-institution record, we continue to find persuasive Petitioner’s argument that a skilled artisan would have found it obvious to add diethanolamine to a treprostinil solution without isolating treprostinil when combining Moriarty with Phares. *See* Pet. 61–62 (citing Ex. 1008, 40; Ex. 1002 ¶¶ 177–178).

Our analysis is consistent with the Board’s previous finding in a related proceeding involving U.S. Patent No. 8,497,393 (“the ’393 patent”), which is a parent of the ’901 patent. *See* Ex. 1001, code (63). The Board previously held that claims of the ’393 patent are unpatentable. Dec. 3 (citing IPR2016-00006, Paper 82 (PTAB Mar. 31, 2017) (“the ’393

Decision” or “the ’393 Dec.”)). In doing so, the Board found that “an ordinarily skilled artisan would have modified the process of Moriarty to incorporate the step of adding and dissolving diethanolamine to treprostinil as taught by Phares to eliminate the requirement for intermediate purification, thus, improving synthetic efficiency and reducing cost.” The ’393 Dec. 47. The Federal Circuit has affirmed that decision. *United Therapeutics Corp. v. SteadyMed Ltd.*, 702 F. App’x. 990 (Fed. Cir. 2017). As we did in the Decision, we continue to “encourage the parties here to discuss whether issue preclusion applies in this proceeding such that Patent Owner cannot reargue this point.” Dec. 25 n.7.

In sum, we are not persuaded that we misapprehended the differences between the prior art and claim 1.

#### *Inherency of the Claimed Product*

Patent Owner contends that “[b]ecause the recited steps are different from those disclosed in Moriarty and Phares (no isolation of treprostinil after alkylation and hydrolysis steps before forming a salt), then the resulting products cannot be assumed to be the same.” Reh’g Req. 5. Patent Owner contends that given the different process steps, Petitioner cannot argue “identical impurities” and “effectively conceded that the resulting impurities may not necessarily be the same as recited in the claims.” *Id.* at 6. On the current record, we are not persuaded by Patent Owner’s argument.

As discussed above, at this stage of the proceeding, we remain persuaded by Petitioner’s argument that the combination of Moriarty and Phares teaches the same process steps, including adding a base to treprostinil solution without isolating treprostinil. Accordingly, we remain persuaded

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.